Most people shopping for a GLP-1 program focus on the wrong thing. They compare the drug name and stop there. The real differences are in the pharmacy, the oversight, the shipping reliability, and whether the price on the homepage survives checkout.
Here is how I break down five programs worth considering in 2026, grouped by what each one actually does best.
For Best Overall Value and Verified Sourcing: HealthRX
Cash-pay compounded GLP-1 telehealth has a pricing problem. Plenty of brands quote a low number and bury pharmacy fees or titration surcharges in fine print. HealthRX quotes $99 per month for compounded semaglutide and $149 for compounded tirzepatide, and the overnight shipping is included, not tacked on. That price spread is genuinely hard to beat right now.
The sourcing is what gives me confidence here. Medication ships from Manifest Pharmacy in Greer, South Carolina, a named 503A/USP-797 compounding pharmacy with LegitScript certification (cert 50087439) and lot-level tracking from production to delivery. Many telehealth brands cannot or will not tell you which lab fills their vials. Manifest is not anonymous. A US board-certified physician reviews the intake assessment within roughly 24 hours, which is fast for a fully cash-pay model, and coverage reaches all 50 states.
Worth saying plainly: compounded semaglutide and tirzepatide are not FDA-approved drugs. They are compounded copies made while brand-name shortages existed. The clinical trial data HealthRX references, around 15 percent average weight loss at 68 weeks for semaglutide (STEP 1) and roughly 21 percent at 72 weeks for tirzepatide (SURMOUNT-1), comes from branded drug trials, not from compounded versions.
Best for: People who want low verified cash pricing and fast shipping without sacrificing pharmacy transparency.
For Published Lab Testing and Broader Peptide Access: FormBlends
If you want to see actual purity numbers before you inject anything, FormBlends is the most transparent option I have come across. The brand publishes per-product HPLC purity results, mass spectrometry identity testing, and endotoxin sterility data with named figures. Not just a claim of “third-party tested.” Real documents.
Compounded semaglutide runs around $299 and tirzepatide around $349, so the pricing is notably higher than HealthRX’s entry points. FormBlends ships to 47 states, not all 50. Those are real limitations. But for someone who will not use a compounded GLP-1 without published assay data, or who wants GLP-1 therapy alongside peptides for recovery, cognition, or longevity from a single clinician-supervised source, FormBlends has that catalog in a way most GLP-1-only telehealth brands do not.
Best for: Detail-oriented buyers who prioritize documented purity testing, or anyone wanting compounded GLP-1s plus a broader peptide program under one roof.
For Insurance Coverage and Brand-Name Meds: Hims & Hers or Ro
Two big names, two slightly different strengths. Hims & Hers exited compounded GLP-1s after the March 2026 Novo Nordisk settlement and now writes for branded medications. Injectable Wegovy runs roughly $299 per month through the platform; with an insurance prior-authorization and a manufacturer savings card, that number can drop to near zero. Oral semaglutide is listed around $249. Zepbound (tirzepatide) comes in at around $399 before any coverage.
Ro Body runs a membership around $39 for month one and $74 to $149 ongoing, with medications billed separately. Ro has a prior-authorization team that handles the insurance paperwork. Both platforms are worth looking at if your employer plan covers anti-obesity medications. Branded drugs also carry FDA approval, which compounded versions do not.
Best for: Insured patients willing to wait for prior-auth who want brand-name drugs.
For Clinical Monitoring and Obesity-Medicine Expertise: Mochi Health
Mochi Health uses board-certified obesity-medicine clinicians rather than general practitioners. Compounded semaglutide sits around $99 per month and tirzepatide around $199. The monitoring is more hands-on than what you get from most cash-pay platforms, which matters if you have metabolic comorbidities or want ongoing dose guidance from a specialist.
Best for: Patients who want a physician with obesity-medicine credentials involved in ongoing care, not just the intake.
For Flexibility and Low Barrier to Entry: PlushCare
PlushCare charges about $19.99 per month for membership and offers same-day telehealth visits. It handles branded meds and accepts insurance. It is not specialized in weight management the way Mochi is, but for someone who already has a GLP-1 prescription and wants a convenient, low-cost platform to continue care or get a prior-auth started, it works.
Best for: People who want quick access to a provider without committing to a weight-loss-specific platform.
A Note Before You Start
None of these programs replaces a conversation with a physician who knows your full medical history. Compounded GLP-1 drugs are not FDA-approved products, and the FDA issued warning letters to more than 30 telehealth and compounding firms in early 2026. Price, convenience, and even pharmacy transparency matter, but so does your own baseline health. Get bloodwork done. Tell your provider about any cardiac, kidney, or GI history before starting.
Common Questions
Does it matter which compounding pharmacy fills my GLP-1 vials?
Yes, and it matters more than most people realize. A 503A pharmacy like Manifest (used by HealthRX) operates under stricter USP-797 sterility standards and is subject to state board oversight. Not every telehealth brand names its compounding partner at all. If a platform will not tell you which pharmacy fills your prescription, that is worth treating as a red flag.
Is the 15 to 21 percent weight loss data actually relevant to compounded semaglutide or tirzepatide?
Not directly. The STEP 1 and SURMOUNT-1 trial results come from branded Ozempic, Wegovy, and Zepbound, not from compounded versions. Compounded GLP-1s may behave similarly, but no equivalent long-term trial data exists for them. Platforms that cite those figures as evidence for their compounded product are borrowing credibility from a different drug.
If my insurance covers weight-loss medication, is there any reason to use a cash-pay platform like HealthRX or Mochi?
Sometimes. Prior-authorization for branded GLP-1s can take weeks and get denied. Cash-pay platforms ship faster and skip that process entirely. If your income makes $99 to $199 per month manageable, starting on compounded medication while your insurance appeal works through the system is a strategy some patients use deliberately.
What happened to Hims & Hers compounded semaglutide, and does it affect current users?
Hims & Hers stopped offering compounded GLP-1s following a March 2026 settlement with Novo Nordisk. The platform now prescribes branded medications only. Anyone who started on compounded semaglutide through Hims & Hers would need to transition to a branded product or switch platforms. This is a concrete reason to track regulatory news if you are mid-program.
How does FormBlends’ published purity data actually compare to what other platforms claim?
Most telehealth platforms say their compounding partner is “third-party tested” without publishing the underlying documents. FormBlends posts HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin results by product. That is a higher level of public disclosure than most competitors offer, though it does not replace FDA oversight and comes at a price premium of roughly $150 to $200 more per month than the lowest-cost options here.
Sources
- FDA: Compounding and the FDCA, 503A pharmacy framework (fda.gov)
- Jastreboff et al., *New England Journal of Medicine*, 2022 (tirzepatide phase 3 efficacy study)
- Wilding et al., *New England Journal of Medicine*, 2021 (semaglutide phase 3 efficacy study)
- LegitScript pharmacy certification database (legitscript.com)
- Novo Nordisk press release on compounded semaglutide settlement, March 2026
- Lilly GLP-1 pricing disclosures via LillyDirect, April 2026
